摘要
目的对加替沙星序贯治疗下呼吸道细菌感染进行药物经济学评价。方法将69例下呼吸道细菌性感染患者,随机分为A组(34例)、B组(35例),其中A组采用加替沙星注射液400m g静脉滴注,每天1次,连用10天;B组先用加替沙星注射液400m g静脉滴注,每天1次,3-4天后改为口服400m g,每天1次,连用6-7天,然后对两种方案进行成本-效果分析。结果两组在临床疗效、不良反应发生率及细菌清除率方面差异无统计学意义(P>0.05);但A组的医疗费用却高于B组(P<0.01)。结论加替沙星序贯疗法与单纯静脉滴注相比更安全,更经济合理。
Objective To evaluate the clinical curative and economic effects of sequential therapy of gatifloxacin injection for bacterial infection of lower respiratory tract （LRT）. Methods 69 cases of bacterial infection of LRT were randomly divided into two groups. 34 cases in Group A were treated with IV injection of Gatiftoxacin, 400 mg qd for 10 days. 35 cases in Group B were treated with IV injection of Gatifloxacin, 400 mg qd for 3-4 days, then given Gatifloxacin capsules, 400 mg qd for 6-7 days. Cost-effectiveness analysis were made after ending the treatment. Results There was no obvious difference between these two schemes in clinical effective rate and bacterial clearance and incidence rate, but cost-effectiveness ratio in Group B was lower than thatin Group A. Conclusion By comparison between sequential therapy of Gatifloxacin and simple IV injection of Gatifloxacin it has been confirmed that the two schemes have a similar curative effect, but the former can obviously decrease total medical cost and so it is worthy to be spread clinically.
出处
《西部医学》
2005年第5期473-474,共2页
Medical Journal of West China
关键词
下呼吸道细菌感染
加替沙星
序贯疗法
药物经济学
Bacterial infection of lower respiratory tract
Gatifloxacin
Sequential therapy
